- Home
- WEA vs DTIL Comparison
WEA vs DTIL Comparison
Compare WEA & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WEA | DTIL |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.2M | 97.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | WEA | DTIL |
|---|---|---|
| Price | $11.25 | $4.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | 46.1K | ★ 269.0K |
| Earning Date | 01-01-0001 | 11-03-2025 |
| Dividend Yield | ★ 7.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $698,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.60 | $3.75 |
| 52 Week High | $11.29 | $8.82 |
Technical Indicators
Market Signals| Indicator | WEA | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 64.30 | 41.63 |
| Support Level | $11.16 | $3.75 |
| Resistance Level | $11.37 | $4.19 |
| Average True Range (ATR) | 0.10 | 0.27 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 74.39 | 39.65 |
Price Performance
Historical ComparisonAbout WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.